|Articles|March 3, 2017
Frost & Sullivan Reveal Asia as Ideal Trial Destination
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials.
Advertisement
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials. The report states that this result is due to vast treatment-naive patient pools, clinical infrastructure and low operational costs.
Read the full report
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research
2
ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN
3
From Study-by-Study to Portfolio Recruitment: Q&A with Gaynor Anders, Trialbee
4
ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy
5